Verastem, Inc. (VSTM) Q3 2025 Earnings Call Transcript [Seeking Alpha]
Verastem, Inc. (VSTM)
Last verastem, inc. earnings: 10/29 04:17 pm
Check Earnings Report
US:NASDAQ Investor Relations:
verastem.com
Company Research
Source: Seeking Alpha
Julissa Viana - Vice President of Corporate Communications & Investor Relations Daniel Paterson - President, CEO & Director Matthew Ros - Chief Operating Officer Michael Crowther - Chief Commercial & Strategy Officer Daniel Calkins - Chief Financial Officer Conference Call Participants Michael Schmidt - Guggenheim Securities, LLC, Research Division Justin Zelin - BTIG, LLC, Research Division Xun Lee - H.C. Wainwright & Co, LLC, Research Division Yuan Zhi - B. Riley Securities, Inc., Research Division Eric Schmidt - Cantor Fitzgerald & Co., Research Division James Molloy - Alliance Global Partners, Research Division Presentation Operator Good morning, and welcome to Verastem Oncology's Third Quarter 2025 Earnings Conference Call. My name is Liz, and I'll be your call operator for today. Please note, this event is being recorded. [Operator Instructions] I will now turn the call over to Julissa Viana, Vice President of Corporate Communications, Investor Relat
Show less
Read more
Impact Snapshot
Event Time:
VSTM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VSTM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VSTM alerts
High impacting Verastem, Inc. news events
Weekly update
A roundup of the hottest topics
VSTM
News
- Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Verastem: Downgrading To Buy Based On RAMP-203 Setback In Targeting KRAS G12C NSCLC [Seeking Alpha]Seeking Alpha
- Verastem (NASDAQ:VSTM) had its "buy" rating reaffirmed by analysts at Guggenheim.MarketBeat
- Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung CancerBusiness Wire
- Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth [Yahoo! Finance]Yahoo! Finance
VSTM
Earnings
- 11/4/25 - Miss
VSTM
Sec Filings
- 1/23/26 - Form 4
- 1/23/26 - Form 4
- 1/14/26 - Form 144
- VSTM's page on the SEC website